Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,259 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in high-risk multiple myeloma.
Murakami H, Fujii H, Inaba T, Shimazaki C, Okamoto S, Miwa A, Sawamura M, Abe M, Chou T, Asaoku H, Kitahara Y, Hayashi K, Kosaka M, Togawa A, Takatsuki K; Japan Myeloma Study Group. Murakami H, et al. Among authors: chou t. Eur J Haematol. 2004 Sep;73(3):169-73. doi: 10.1111/j.1600-0609.2004.00282.x. Eur J Haematol. 2004. PMID: 15287913 Clinical Trial.
Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma.
Sunami K, Shinagawa K, Sawamura M, Sakai A, Saburi Y, Imamura Y, Mizuno I, Tamaki S, Kamimura T, Tsuda H, Gondo H, Hino N, Shimazaki C, Miyata A, Tajima F, Takemoto Y, Miwa A, Chou T, Harada M. Sunami K, et al. Among authors: chou t. Int J Hematol. 2009 Dec;90(5):635-642. doi: 10.1007/s12185-009-0445-8. Epub 2009 Nov 21. Int J Hematol. 2009. PMID: 19936876 Clinical Trial.
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K; Japanese Society of Myeloma; European Myeloma Network. Ozaki S, et al. Among authors: chou t. Acta Haematol. 2014;132(2):211-9. doi: 10.1159/000357394. Acta Haematol. 2014. PMID: 24662986 Free article.
Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
Ozaki S, Handa H, Saitoh T, Murakami H, Itagaki M, Asaoku H, Suzuki K, Isoda A, Matsumoto M, Sawamura M, Konishi J, Sunami K, Takezako N, Hagiwara S, Kuroda Y, Chou T, Nagura E, Shimizu K. Ozaki S, et al. Among authors: chou t. Blood Cancer J. 2015 Sep 18;5(9):e349. doi: 10.1038/bcj.2015.79. Blood Cancer J. 2015. PMID: 26383822 Free PMC article. No abstract available.
Bortezomib maintenance therapy in transplant-ineligible myeloma patients who plateaued after bortezomib-based induction therapy: a multicenter phase II clinical trial.
Isoda A, Murayama K, Ito S, Kohara Y, Iino M, Miyazawa Y, Matsumoto M, Handa H, Imai Y, Ishiguro T, Izumita W, Kitano K, Hirabayashi Y, Nakazawa H, Ishida F, Mitsumori T, Kirito K, Chou T, Murakami H; Kanshinetsu Multiple Myeloma Study Group. Isoda A, et al. Among authors: chou t. Int J Hematol. 2018 Jul;108(1):39-46. doi: 10.1007/s12185-018-2448-9. Epub 2018 Mar 28. Int J Hematol. 2018. PMID: 29594921 Clinical Trial.
2,259 results